Institutional Special Needs Plan

Part D Prior Authorization List

## **ABIRATERONE**

### **Products Affected**

* *abiraterone acetate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Castration-resistant metastatic prostate cancer and used in combination with prednisone, or B.) High risk, castration-sensitive metastatic prostate cancer and used in combination with prednisone |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or urologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ACITRETIN**

### **Products Affected**

* *acitretin*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Severely impaired liver or kidney function, B.) Chronic abnormally elevated blood lipid values, C.) Concomitant use of methotrexate or tetracyclines, D.) Pregnancy |
| **Required Medical Information** | Diagnosis of severe, recalcitrant psoriasis (including plaque, guttate, erythrodermic palmar- plantar and pustular) AND patient must have tried and failed, contraindication or intolerance to one formulary first line agent (e.g., Topical Corticosteroids (betamethasone, fluocinonide, desoximetasone),Topical Calcipotriene/Calcitriol, Topical Calcipotriene, OR Topical Tazarotene) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a dermatologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ACTIMMUNE**

### **Products Affected**

* ACTIMMUNE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Chronic granulomatous disease for use in reducing the frequency and severity of serious infections, or B.) Severe, malignant osteopetrosis (SMO) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ADEMPAS**

### **Products Affected**

* ADEMPAS

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant administration with nitrates or nitric oxide donors (such as amyl nitrate) in any form, B.) Concomitant administration with phosphodiesterase inhibitors, including specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or non-specific PDE inhibitors (such as dipyridamole or theophylline), C.) Pregnancy, or D.) Patients with pulmonary hypertension associated with idiopathic interstitial pneumonia |
| **Required Medical Information** | Diagnosis of one of the following A.) Pulmonary arterial hypertension (WHO group I) and diagnosis was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.), or B.) Chronic thromboembolic pulmonary hypertension (CTEPH, WHO group 4) and patient has persistent or recurrent disease after surgical treatment (e.g., pulmonary endarterectomy) or has CTEPH that is inoperable (Female patients must be enrolled in the ADEMPAS REMS program) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a cardiologist or pulmonologist |
| **Coverage Duration** | Initial: 6 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **AFINITOR**

### **Products Affected**

* *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Hypersensitivity to everolimus, or B.) Hypersensitivity to rapamycin derivatives (e.g. sirolimus) |
| **Required Medical Information** | Diagnosis of one of the following A.) Renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery, B.) Advanced hormone receptor-positive, HER2 negative breast cancer in postmenopausal women and taken in combination with exemestane, after failure with letrozole or anastrozole, C.) Progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin and disease is unresectable, locally advanced, or metastatic, D.) Pancreatic progressive neuroendocrine tumors and disease is unresectable, locally advanced, or metastatic, E.) Advanced renal cell carcinoma (RCC) after failure with sunitinib or sorafenib, F.) Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in patients who are not candidates for curative surgical resection |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ALECENSA**

### **Products Affected**

* ALECENSA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of metastatic anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer as detected by an FDA-approved test |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ALOSETRON**

### **Products Affected**

* *alosetron hcl*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Constipation, B.) History of Chronic or severe constipation or sequelae from constipation, C.) History of ischemic colitis, intestinal obstruction, stricture, toxic megacolon, GI perforation, adhesions, diverticulitis, Crohns disease, ulcerative colitis, D.) History of severe hepatic impairment, E.) History of impaired intestinal circulation, thrombophlebitis, or hypercoagulable state, or F.) Coadministration with fluvoxamine |
| **Required Medical Information** | Diagnosis of irritable bowel syndrome, severe diarrhea-predominant |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ALPHA-1 PROTEINASE INHIBITOR**

### **Products Affected**

* PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Immunoglobulin A (IgA) deficiency with antibodies against IgA |
| **Required Medical Information** | Diagnosis of alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency in adult patients with emphysema |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a pulmonologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ALUNBRIG**

### **Products Affected**

* ALUNBRIG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of anaplastic lymphoma kinase-positive (ALK) metastatic non-small cell lung cancer (NSCLC) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **AMBRISENTAN**

### **Products Affected**

* *ambrisentan*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Pregnancy, or B.) Idiopathic pulmonary fibrosis (IPF), including those with pulmonary hypertension |
| **Required Medical Information** | Diagnosis of pulmonary arterial hypertension classified as WHO Group I, confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a cardiologist or pulmonologist |
| **Coverage Duration** | Initial: 6 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ARCALYST**

### **Products Affected**

* ARCALYST

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), B.) Deficiency of interleukin-1 receptor antagonist (DIRA) and patient requires maintenance therapy for remission, or C.) Recurrent pericarditis (RP) and reduction in risk of recurrence |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ARIKAYCE**

### **Products Affected**

* ARIKAYCE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Known sensitivity to any aminoglycoside |
| **Required Medical Information** | Diagnosis of pulmonary Mycobacterium avium complex (MAC) infection and used as part of a combination antibacterial regimen in treatment refractory patients (greater than 6 months of a multidrug background regimen) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an infectious disease specialist or pulmonologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **AURYXIA**

### **Products Affected**

* AURYXIA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Iron overload syndrome (e.g. hemochromatosis) |
| **Required Medical Information** | Diagnosis of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a hematologist or nephrologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | Ferric Citrate is NOT approvable for iron deficiency anemia per Part D law |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **AUSTEDO**

### **Products Affected**

* AUSTEDO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Suicidal ideation and/or untreated or inadequately treated depression in a patient with Huntington's Disease, B.) Hepatic impairment, C.) Concomitant use of MAOIs, reserpine, tetrabenazine, or valbenazine |
| **Required Medical Information** | Diagnosis of one of the following A.) Chorea associated with Huntington's disease (Huntington's chorea), or B.) Tardive dyskinesia |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist or psychiatrist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **AYVAKIT**

### **Products Affected**

* AYVAKIT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Unresectable or metastatic gastrointestinal stromal tumor, with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations, or B.) Advanced Systemic Mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SMAHN), or mast cell leukemia (MCL), and platelet count of at least 50,000/mcL |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BALVERSA**

### **Products Affected**

* BALVERSA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of locally advanced or metastatic urothelial carcinoma and both of the following 1.) Susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations confirmed by an FDA-approved diagnostic test, and 2.) Patient has progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or urologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BENLYSTA**

### **Products Affected**

* BENLYSTA SUBCUTANEOUS

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Active, autoantibody-positive, system lupus erythematosus (SLE), or B.) Active lupus nephritis and patient is receiving standard therapy |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a nephrologist or rheumatologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BESREMI**

### **Products Affected**

* BESREMI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Existence of, or history of severe psychiatric disorders (severe depression, suicidal ideation, or suicide attempt), B.) Hypersensitivity to interferons including interferon alfa-2b or excipients, C.) Hepatic impairment (Child-Pugh B or C), D.) History or presence of active serious or untreated autoimmune disease, or E.) Immunosuppressed transplant recipients |
| **Required Medical Information** | Diagnosis of polycythemia vera |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BEXAROTENE GEL**

### **Products Affected**

* *bexarotene external*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of primary cutaneous T-cell lymphoma (CTCL Stage 1A/1B) and patient had an inadequate response, is intolerant to, or has a contraindication to at least one prior systemic therapy (e.g., corticosteroids) indicated for cutaneous manifestations of CTCL |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or dermatologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BEXAROTENE ORAL**

### **Products Affected**

* *bexarotene oral*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of cutaneous T-cell lymphoma (CTCL) and patient is not a candidate for or had an inadequate response, is intolerant to, or has a contraindication to at least one prior systemic therapy (e.g., corticosteroids) for cutaneous manifestations of CTCL |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Pending CMS Review |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BOSENTAN**

### **Products Affected**

* *bosentan*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant cyclosporine A or glyburide therapy, or B.) Pregnancy |
| **Required Medical Information** | Diagnosis of pulmonary arterial hypertension (WHO Group I) and patient has New York Heart Association (NYHA) Functional Class II-IV, confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e. g., patient is frail, elderly, etc.) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a cardiologist or pulmonologist |
| **Coverage Duration** | Initial: 6 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BOSULIF**

### **Products Affected**

* BOSULIF

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or inadequate response to prior therapy, or B.) Newly diagnosed chronic phase Philadelphia chromosome-positive (Ph+) CML |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BRAFTOVI**

### **Products Affected**

* BRAFTOVI ORAL CAPSULE 75 MG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) unresectable or metastatic melanoma with documented BRAF V600E or V600K mutation as detected by a FDA-approved test and used in combination with binimetinib, or B.) metastatic colorectal cancer with documented BRAF V600E mutation as detected by a FDA-approved test, patient has received prior therapy, and braftovi used in combination with cetuximab. |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **BRUKINSA**

### **Products Affected**

* BRUKINSA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following: A.) mantle cell lymphoma (MCL) and patient has received at least one prior therapy or B.) Treatment of adult patients with Waldenstrom macroglobulinemia or C.) Treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CABOMETYX**

### **Products Affected**

* CABOMETYX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Advanced renal cell carcinoma, B.) Advanced hepatocellular carcinoma (HCC) and patient has been previously treated with sorafenib, C.) Advanced renal cell carcinoma and used as first line treatment in combination with nivolumab or D.) treatment of adults and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CALQUENCE**

### **Products Affected**

* CALQUENCE ORAL CAPSULE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Mantle cell lymphoma (MCL) and patient has received at least 1 prior therapy, B.) Chronic lymphocytic leukemia (CLL), or C.) Small lymphocytic lymphoma (SLL) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CAMZYOS**

### **Products Affected**

* CAMZYOS

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) in adult patients |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CAPRELSA**

### **Products Affected**

* CAPRELSA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Congenital long QT syndrome |
| **Required Medical Information** | Diagnosis of metastatic or unresectable locally advanced medullary thyroid cancer (MTC) AND disease is symptomatic or progressive |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CARGLUMIC ACID**

### **Products Affected**

* *carglumic acid oral tablet soluble*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) N-acetyl glutamate synthase (NAGS) deficiency (confirmed by appropriate genetic testing) with acute or chronic hyperammonemia, or B.) Propionic or methylmalonic acidemia with acute hyperammonemia |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CAYSTON**

### **Products Affected**

* CAYSTON

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of cystic fibrosis (confirmed by appropriate diagnostic or genetic testing) and patient has Pseudomonas aeruginosa lung infection confirmed by positive culture |
| **Age Restrictions** | 7 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CNS STIMULANTS**

### **Products Affected**

* *armodafinil*
* *modafinil*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Obstructive sleep apnea (OSA) confirmed by sleep lab evaluation, B.) Narcolepsy confirmed by sleep lab evaluation, or C.) Shift work disorder (SWD) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **COMETRIQ**

### **Products Affected**

* COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
* COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
* COMETRIQ (60 MG DAILY DOSE)

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of progressive, metastatic medullary thyroid cancer |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **COPIKTRA**

### **Products Affected**

* COPIKTRA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CORLANOR**

### **Products Affected**

* CORLANOR ORAL TABLET

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Decompensated acute heart failure, B.) hypotension (i.e. blood pressure less than 90/50 mmHg), C.) sick sinus syndrome or sinoatrial block or 3rd degree AV block (unless a functioning demand pacemaker is present), D.) bradycardia (i.e., resting heart rate less than 60 bpm prior to treatment), E.) Severe hepatic impairment (Child-Pugh C), F.) Pacemaker dependent (heart rate maintained exclusively by the pacemaker), G.) Concomitant use of strong CYP3A4 inhibitors |
| **Required Medical Information** | Diagnosis of one of the following A.) stable, symptomatic chronic heart failure with left ventricular ejection fraction 35% or less, who are in sinus rhythm with resting heart rate 70 beats per minute or more and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use, or B.) stable, symptomatic heart failure due to dilated cardiomyopathy in patients who are in sinus rhythm with an elevated heart rate |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **COSENTYX**

### **Products Affected**

* COSENTYX (300 MG DOSE)
* COSENTYX SENSOREADY (300 MG)
* COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Ankylosing spondylitis and patient has trial and failure, contraindication, or intolerance to two preferred products, (i.e. Humira, Enbrel), B.) Moderate to severe plaque psoriasis in adults and patient has trail and failure, contraindication, or intolerance to two preferred products, (i.e. Humira, Enbrel, Skyrizi, Stelara), C.) Moderate to severe plaque psoriasis in patients 6 years to less than 18 years of age and patient has trial and failure, contraindication, or intolerance to two preferred products, (i.e. Enbrel, Stelara), D.) Active psoriatic arthritis in adult patient and has trial and failure, contraindication, or intolerance to two preferred products, (i.e. Humira, Enbrel, Stelara), E.) Active psoriatic arthritis in patients 2 years to less than 18 years of age, F.) Non-radiographic axial spondyloarthritis or G.) Active enthesitis-related arthritis |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | Screening for latent tuberculosis infection is required prior to initiation of treatment |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **COTELLIC**

### **Products Affected**

* COTELLIC

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of unresectable or metastatic malignant melanoma with BRAF V600E OR V600K mutation, and documentation of combination therapy with vemurafenib (Zelboraf) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CYSTAGON**

### **Products Affected**

* CYSTAGON

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Known serious hypersensitivity to penicillamine or cysteamine |
| **Required Medical Information** | Diagnosis of nephropathic cystinosis confirmed by the presence of increased cystine concentration in leukocytes or by genetic testing |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **CYSTEAMINE OPHTH**

### **Products Affected**

* CYSTADROPS
* CYSTARAN

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of cystinosis and patient has corneal cystine crystal accumulation |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DALFAMPRIDINE**

### **Products Affected**

* *dalfampridine er*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) History of seizure. B.) Moderate or severe renal impairment (creatinine clearance less than or equal to 50 mL/minute) |
| **Required Medical Information** | Diagnosis of multiple sclerosis and patient must demonstrate sustained walking impairment, but with the ability to walk 25 feet (with or without assistance) prior to starting dalfampridine |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DAURISMO**

### **Products Affected**

* DAURISMO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of newly diagnosed acute myeloid leukemia (AML) and used in combination with cytarabine in patients 75 years of age or older OR in patients that have comorbidities that preclude use of intensive induction chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DEFERASIROX**

### **Products Affected**

* *deferasirox granules*
* *deferasirox oral tablet*
* *deferasirox oral tablet soluble*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Creatinine clearance less than 40 mL/min, B.) Poor performance status, C.) Platelet count less than 50 x 10(9)/L, D.) Advanced malignancy, E.) High-risk myelodysplastic syndrome (MDS) |
| **Required Medical Information** | Diagnosis of one of the following A.) Chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes who have liver iron concentrations of at least 5 mg Fe/g dry weight AND serum ferritin level greater than 300 mcg/L, or B.) Chronic iron overload due to blood transfusions (transfusion hemosiderosis) as evidenced by transfusion of at least 100 mL/kg packed red blood cells AND serum ferritin level greater than 1000 mcg/L |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DEFERIPRONE**

### **Products Affected**

* *deferiprone*
* FERRIPROX ORAL SOLUTION
* FERRIPROX TWICE-A-DAY

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Must meet all of the following 1.) Diagnosis of transfusional iron overload due to thalassemia syndromes, sickle cell disease, or other anemias, 2.) Patient has failed prior chelation therapy, and 3.) Patient has an absolute neutrophil count greater than 1.5 x 10(9)/L |
| **Age Restrictions** | Pending CMS Review |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DIACOMIT**

### **Products Affected**

* DIACOMIT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of severe myoclonic epilepsy in infancy (Dravet syndrome) in patients taking clobazam |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DICLOFENAC TOPICAL**

### **Products Affected**

* *diclofenac sodium external gel 3 %*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of Actinic keratosis |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DIMETHYL FUMARATE**

### **Products Affected**

* *dimethyl fumarate oral*
* *dimethyl fumarate starter pack*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DRONABINOL**

### **Products Affected**

* *dronabinol*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Sesame oil hypersensitivity |
| **Required Medical Information** | Diagnosis of one of the following A.) Anorexia associated to AIDS, or B.) Chemotherapy-induced nausea and vomiting |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 6 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DROXIDOPA**

### **Products Affected**

* *droxidopa*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (e.g., Parkinson disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **DUPIXENT**

### **Products Affected**

* DUPIXENT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | Pending CMS Review |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **EMGALITY**

### **Products Affected**

* EMGALITY

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Chronic or episodic migraine disorder and patient has documented trial, inadequate response, or contraindication to at least 2 generic formulary drugs used for migraine prevention (i.e., propranolol, topiramate, divalproex, timolol), or B.) Episodic cluster headache |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **EMSAM**

### **Products Affected**

* EMSAM

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant use with any of the following: SSRIs, SNRIs, clomipramine, imipramine, meperidine, tramadol, methadone, pentazocine, propoxyphene, dextromethorphan, carbamazepine, or B.) Pheochromocytoma |
| **Required Medical Information** | Diagnosis of major depressive disorder and patient had trial of at least 2 generic oral antidepressants from differing classes (at least one should be from the following list: selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, mirtazapine, or bupropion unless contraindicated), unless unable to take any oral medication AND Patient had an adequate washout period (for patients previously on agents requiring a washout period) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ENBREL**

### **Products Affected**

* ENBREL MINI
* ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
* ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
* ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
* ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, or E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | Screening for latent tuberculosis infection is required prior to initiation of treatment |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ENDARI**

### **Products Affected**

* ENDARI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of sickle cell disease AND one of the following 1.) Patient has acute complications and is being treated with Hydroxyurea, or 2.) Patient has acute complications and is unable to tolerate Hydroxyurea |
| **Age Restrictions** | 5 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **EPIDIOLEX**

### **Products Affected**

* EPIDIOLEX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Lennox-Gastaut syndrome, B.) Severe myoclonic epilepsy in infancy (Dravet syndrome), or C.) Seizures associated with tuberous sclerosis complex (TSC) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **EPOETIN THERAPY**

### **Products Affected**

* RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Non-myeloid neoplastic disease and utilized for the treatment of chemotherapy induced anemia, B.) HIV infection and utilized for the treatment of zidovudine induced anemia, C.) Chronic kidney disease resulting in anemia, or D.) High risk surgical candidate status at risk for perioperative blood loss and undergoing elective, noncardiac, or nonvascular surgery |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ERIVEDGE**

### **Products Affected**

* ERIVEDGE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Metastatic basal cell carcinoma, or B.) Locally advanced basal cell carcinoma that has recurred following surgery or the patient is not a candidate for surgery or radiation |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ERLEADA**

### **Products Affected**

* ERLEADA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Nonmetastatic, castration-resistant prostate cancer, or B.) Metastatic, castration-sensitive prostate cancer |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or urologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ERLOTINIB**

### **Products Affected**

* *erlotinib hcl*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Locally advanced, unresectable, or metastatic pancreatic cancer and erlotinib will be used in combination with gemcitabine, B.) Locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility AND one of the following 1.) Erlotinib will be used as first-line treatment, 2.) Failure with at least one prior chemotherapy regimen, or 3.) No evidence of disease progression after four cycles of first-line platinum-based chemotherapy and erlotinib will be used as maintenance treatment |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ESBRIET**

### **Products Affected**

* ESBRIET ORAL CAPSULE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of idiopathic pulmonary fibrosis |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a pulmonologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **EVEROLIMUS SUSPENSION**

### **Products Affected**

* *everolimus oral tablet soluble*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Hypersensitivity to everolimus , or B.) Hypersensitivity to rapamycin derivatives (e.g. sirolimus) |
| **Required Medical Information** | Diagnosis of one of the following A.) Tuberous sclerosis complex (TSC)-associated partial-onset seizures, or B.) Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in patients who are not candidates for curative surgical resection |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **EVRYSDI**

### **Products Affected**

* EVRYSDI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of spinal muscular atrophy (SMA) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **EXKIVITY**

### **Products Affected**

* EXKIVITY

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (as confirmed by an FDA-approved test) AND whose disease has progressed on or after platinum-based chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **FENTANYL ORAL**

### **Products Affected**

* *fentanyl citrate buccal lozenge on a handle*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Management of acute or postoperative pain (including headache/migraine, dental pain, and use in the emergency room), B.) Use in opioid non-tolerant patients, C.) Known or suspected gastrointestinal obstruction, including paralytic ileus, D.) Acute or severe bronchial asthma and used in an unmonitored setting (absence of resuscitative equipment) |
| **Required Medical Information** | Must meet all of the following 1.) Diagnosis of cancer-related breakthrough pain, 2.) Patient is currently receiving/tolerant to around-the-clock opioid therapy for persistent cancer pain, and 3.) Patient and prescriber are enrolled in the TIRF REMS Access Program |
| **Age Restrictions** | 16 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **FENTANYL PATCH**

### **Products Affected**

* *fentanyl*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Management of acute or postoperative pain (including headache/migraine, dental pain, and use in the emergency room), B.) Mild or intermittent pain management, C.) Use in opioid non-tolerant patients, D.) Known or suspected gastrointestinal obstruction, including paralytic ileus, E.) Acute or severe bronchial asthma and used in an unmonitored setting (absence of resuscitative equipment) |
| **Required Medical Information** | Must meet all of the following 1.) Patient is opioid tolerant (taking for one week or longer at least 60mg of morphine or equivalent daily) and 2.) Patient has tried at least one extended release oral opioids or is unable to take extended release oral opioids secondary to allergy, adverse events, swallowing difficulty, or uncontrollable nausea/vomiting |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **FINTEPLA**

### **Products Affected**

* FINTEPLA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant use of an MAOI, or B.) Use within 14 days of discontinuing an MAOI |
| **Required Medical Information** | Diagnosis of Severe myoclonic epilepsy in infancy (Dravet syndrome) or seizures associated with Lennox-Gastaut syndrome |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **FOTIVDA**

### **Products Affected**

* FOTIVDA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of relapsed or refractory advanced renal cell cancer (RCC) following 2 or more prior systemic therapies |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **GATTEX**

### **Products Affected**

* GATTEX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of short bowel syndrome and patient is dependent on parenteral support |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **GAVRETO**

### **Products Affected**

* GAVRETO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test, B.) Advanced or metastatic RET-mutant medullary thyroid cancer and patient requires systemic therapy, or C.) Advanced or metastatic RET fusion-positive thyroid and patient requires systemic therapy and is radioactive iodine-refractory, when radioactive iodine is appropriate |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **GILENYA**

### **Products Affected**

* GILENYA ORAL CAPSULE 0.5 MG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Recent (within the last 6 months) occurrence of: myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure, B.) History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker, C.) Baseline QTC interval greater than or equal to 500 milliseconds, D.) Receiving concurrent treatment with Class Ia or Class III anti-arrhythmic drugs (quinidine, procainamide, amiodarone, sotalol) |
| **Required Medical Information** | Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis |
| **Age Restrictions** | 10 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **GILOTRIF**

### **Products Affected**

* GILOTRIF

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test, or B.) Metastatic squamous NSCLC with progression after platinum-based chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **GLATIRAMER**

### **Products Affected**

* COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
* *glatiramer acetate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **GROWTH HORMONE**

### **Products Affected**

* OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
* OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Use for growth promotion in pediatric patients with closed epiphyses, B.) Acute critical illness caused by complications following open-heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure, C.) Active malignancy, D.) Active proliferative or severe nonproliferative diabetic retinopathy, E.) Prader-Willi Syndrome in patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an Endocrinologist or Nephrologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **HEPATITIS B**

### **Products Affected**

* *adefovir dipivoxil*
* BARACLUDE ORAL SOLUTION
* *entecavir*
* VEMLIDY

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of chronic hepatitis B and all of the following 1.) Patient has or had evidence of viral replication prior to initiation, 2.) Patient has evidence of persistent elevations in serum aminotransferase (ALT or AST) or histologically active disease, and 3.) Patient is receiving anti-retroviral therapy if the patient has HIV co-infection |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **HEPATITIS C**

### **Products Affected**

* MAVYRET
* *sofosbuvir-velpatasvir*
* VOSEVI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of HCV genotype, subtype and quantitative HCV RNA (viral load) testing any time prior to therapy. Must document cirrhosis status, prior treatment history (if any), and planned duration of treatment. All genotypes will require trial/failure, contraindication to, or intolerance to Mavyret or Sofosbuvir-Velpatasvir prior to the approval of Vosevi. |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist |
| **Coverage Duration** | Duration of approval per AASLD Guidelines |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **HRM ANTIPSYCHOTIC**

### **Products Affected**

* *aripiprazole*
* *asenapine maleate*
* CAPLYTA ORAL CAPSULE 42 MG
* *chlorpromazine hcl oral*
* *clozapine*
* FANAPT
* FANAPT TITRATION PACK
* *fluphenazine hcl injection*
* *fluphenazine hcl oral*
* *haloperidol lactate*
* *haloperidol oral*
* LATUDA
* *loxapine succinate oral*
* LYBALVI
* *molindone hcl*
* NUPLAZID ORAL CAPSULE
* NUPLAZID ORAL TABLET 10 MG
* *olanzapine*
* *paliperidone er*
* *perphenazine oral*
* *quetiapine fumarate er*
* *quetiapine fumarate oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg*
* REXULTI
* *risperidone*
* SECUADO
* *thioridazine hcl oral*
* *thiothixene oral*
* *trifluoperazine hcl oral*
* VERSACLOZ
* VRAYLAR
* *ziprasidone hcl*
* *ziprasidone mesylate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Diagnosis of dementia-related psychosis, in the absence of other compendia supported indications not otherwise excluded from Part D |
| **Required Medical Information** | For patients greater than or equal to 65 years old, who have had at least 1 claim for any dementia medication (donepezil, galantamine, rivastigmine, memantine or Namzaric) within the past 120 days, a coverage determination will be approved for FDA-approved indications not otherwise excluded from Part D. |
| **Age Restrictions** | Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older. |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **HUMIRA**

### **Products Affected**

* HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML
* HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
* HUMIRA PEN-CD/UC/HS STARTER
* HUMIRA PEN-PEDIATRIC UC START
* HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML
* HUMIRA PEN-PSOR/UVEIT STARTER
* HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate, F.) Moderate to severe Crohn's disease in patients who have had an inadequate response to conventional therapy, G.) Moderate to severe ulcerative colitis in patients who have had an inadequate response to immunosuppressants (e.g. corticosteroids, azathioprine), H.) Non-infectious uveitis (including intermediate, posterior, and panuveitis), or I.) Moderate to severe hidradenitis suppurativa |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | Screening for latent tuberculosis infection is required prior to initiation of treatment |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **IBRANCE**

### **Products Affected**

* IBRANCE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer used in combination with fulvestrant and disease has progressed following endocrine therapy, or B.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and used in combination with an aromatase inhibitor in a male or postmenopausal female patient as initial endocrine-based therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ICATIBANT**

### **Products Affected**

* FIRAZYR
* *icatibant acetate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following and used as treatment for acute attacks A.) Hereditary angioedema (HAE) with C1 inhibitor deficiency (Type 1) confirmed by laboratory testing, or B.) HAE with C1 inhibitor dysfunction (Type 2) confirmed by laboratory testing, or C.) HAE with normal C1 inhibitor (Type 3) confirmed by laboratory testing and one of the following 1.) Positive test for an F12, angiopoietin-1, or plasminogen gene mutation, or 2.) Family history of angioedema and the angioedema was refractory to a trial of an antihistamine for at least one month |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an allergist, hematologist, or immunologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ICLUSIG**

### **Products Affected**

* ICLUSIG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) in adult patients who are T315I-positive or for whom no other tyrosine kinase inhibitor therapy is indicated, B.) Chronic phase, chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to at least two prior kinase inhibitors, or C.) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients who are T315I-positive or for whom no other tyrosine kinase inhibitor therapy is indicated |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **IDHIFA**

### **Products Affected**

* IDHIFA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation as detected by an FDA approved test |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **IMATINIB**

### **Products Affected**

* *imatinib mesylate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), B.) Ph+ acute lymphoblastic leukemia (ALL), C.) Gastrointestinal stromal tumor (GIST) where patient has documented c-KIT (CD117) positive unresectable or metastatic malignant GIST or patient had resection of c-KIT positive GIST and imatinib will be used as an adjuvant therapy, D.) Dermatofibrosarcoma protuberans that is unresectable, recurrent, or metastatic, E.) Hypereosinophilic syndrome or chronic eosinophilic leukemia, F.) Myelodysplastic syndrome or myeloproliferative disease associated with platelet-derived growth factor receptor gene re-arrangements, or G.) Aggressive systemic mastocytosis without the D816V c-KIT mutation or with c-KIT mutational status unknown |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **IMBRUVICA**

### **Products Affected**

* IMBRUVICA ORAL CAPSULE
* IMBRUVICA ORAL TABLET

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Mantle cell lymphoma (MCL) and patient has received at least one prior therapy, B.) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL), C.) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, D.) Waldenstrom's macroglobulinemia (WM), E.) Marginal zone lymphoma (MZL) and patient requires systemic therapy and has received at least one prior anti-CD20-based therapy, or F.) Chronic graft vs host disease (cGVHD) after failure of at least one first-line corticosteroid therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **INBRIJA**

### **Products Affected**

* INBRIJA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concurrent use with nonselective monoamine oxidase inhibitors (MAOIs) (e.g. phenelzine and tranylcypromine), B.) Recent use (within 2 weeks) with a nonselective MAOI |
| **Required Medical Information** | Must meet all of the following A.) Diagnosis of Parkinson's disease and used for intermittent treatment of off episodes, and B.) Concurrent therapy with carbidopa/levodopa |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **INCRELEX**

### **Products Affected**

* INCRELEX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Active or suspected malignancy, B.) Use for growth promotion in patients with closed epiphyses, or C.) Intravenous administration |
| **Required Medical Information** | Diagnosis of one of the following A.) Severe primary insulin-like growth factor-1 (IGF-1) deficiency and utilized for pediatric treatment of growth failure, or B.) Growth hormone (GH) gene deletion and patient has developed neutralizing antibodies to GH and utilized for pediatric treatment of growth failure |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **INGREZZA**

### **Products Affected**

* INGREZZA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of tardive dyskinesia |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist or psychiatrist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **INJECTABLE TESTOSTERONE**

### **Products Affected**

* *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*
* *testosterone enanthate intramuscular solution*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Carcinoma of the breast (males only), B.) Known or suspected carcinoma of the prostate, C.) Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Hypogonadotropic hypogonadism, B.) Inoperable metastatic breast cancer in women who are postmenopausal (testosterone enanthate), C.) Primary hypogonadism, or D.) Delayed puberty (testosterone enanthate). Diagnosis of hypogonadism must be confirmed by a low-for-age serum testosterone (total or free) level defined by the normal laboratory reference value |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **INLYTA**

### **Products Affected**

* INLYTA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Advanced renal cell carcinoma and patient failed one or more systemic therapies for renal cell carcinoma (e.g., sunitinib-, bevacizumab-, temsirolimus-, or cytokine-containing regimens), or B.) Advanced renal cell carcinoma and used as first-line therapy in combination with avelumab or pembrolizumab |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **INQOVI**

### **Products Affected**

* INQOVI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **INREBIC**

### **Products Affected**

* INREBIC

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **INTRON A**

### **Products Affected**

* INTRON A INJECTION SOLUTION RECONSTITUTED

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Autoimmune hepatitis, B.) Decompensated liver disease, C.) Pregnancy, D.) When used in combination with ribavirin: hemoglobinopathies (e.g., thalassemia major, sickle cell anemia), men with female partners who are pregnant, renal function impairment (CrCl less than 50 mL/min) |
| **Required Medical Information** | Diagnosis of one of the following A.) Hairy cell leukemia, B.) Condylomata acuminata involving external surfaces to the genital or perianal areas, C.) AIDS-related Kaposi's sarcoma, D.) Clinically aggressive follicular lymphoma and the medication will be used concurrently with anthracycline-containing chemotherapy or is not a candidate for anthracycline-containing chemotherapy, E.) Malignant melanoma and the request for coverage is within 56 days of surgery and the patient is at high risk of disease recurrence, F.) Chronic hepatitis B with compensated liver disease and patient has or had evidence of hepatitis B viral replication prior to initiation and patient has been serum hepatitis B surface antigen-positive for at least 6 months, or G.) Chronic hepatitis C with compensated liver disease and is receiving combination therapy with ribavirin, unless ribavirin is contraindicated, and the medication will not be used as part of triple therapy with a protease inhibitor and patient has a clinical reason for not using peginterferon |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | Condylomata: 3 months, HBV E antigen positive and Kaposi sarcoma: 16 weeks, Other: 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **IRESSA**

### **Products Affected**

* IRESSA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of metastatic non-small cell lung cancer (NSCLC) and must meet all of the following 1.) Tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility and 2.) Used as first-line treatment |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ISTURISA**

### **Products Affected**

* ISTURISA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of Cushing's disease in patients for whom pituitary surgery is not an option or has not been curative |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an endocrinologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ITRACONAZOLE**

### **Products Affected**

* *itraconazole oral*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Ventricular dysfunction (e.g., congestive heart failure (CHF) or history of CHF), B.) Concurrent therapy with a CYP3A4 substrate (e.g., methadone, lovastatin, simvastatin, etc.), C.) Concurrent use of CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, quinidine, terbinafine), D.) Renal or hepatic impairment and concomitant use of colchicine, fesoterodine, solifenacin, or telithromycin, E.) Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Systemic fungal infection (e.g., aspergillosis, histoplasmosis, blastomycosis), or B.) Onychomycosis confirmed by one of the following: positive potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 6 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ITRACONAZOLE SOLN**

### **Products Affected**

* *itraconazole oral*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Ventricular dysfunction (e.g., congestive heart failure (CHF) or history of CHF), B.) Concurrent therapy with a CYP3A4 substrate (e.g., methadone, lovastatin, simvastatin, etc.), C.) Concurrent use of CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, quinidine, terbinafine), D.) Renal or hepatic impairment and concomitant use of colchicine, fesoterodine, solifenacin, or telithromycin, E.) Pregnancy |
| **Required Medical Information** | Diagnosis of candidiasis (esophageal or oropharyngeal) that is refractory to treatment with fluconazole |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 6 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **IVERMECTIN**

### **Products Affected**

* *ivermectin oral*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Prevention or treatment of COVID-19 |
| **Required Medical Information** | Diagnosis of one of the following: A.) Strongyloidiasis of the intestinal tract or B.) Onchocerciasis |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 1 month |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **JAKAFI**

### **Products Affected**

* JAKAFI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis, B.) Polycythemia vera AND patient has had an inadequate response to or is intolerant of hydroxyurea, C.) Acute graft versus host disease AND disease is refractory to steroid therapy, or D.) Chronic graft-versus-host disease (cGVHD) after failure of corticosteroid therapy (alone or in combination with a calcineurin inhibitor) and up to one additional line of systemic therapy |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 6 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **JUXTAPID**

### **Products Affected**

* JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Moderate to severe liver impairment or active liver disease including unexplained persistent abnormal liver function tests, B.) Pregnancy, or C.) Concomitant use with strong or moderate CYP3A4 inhibitors |
| **Required Medical Information** | Diagnosis of HoFH as confirmed by one of the following A.) Genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (LDLRAP1 or ARH), or B.) Both of the following 1.) Either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL, and 2.) Either xanthoma before 10 years of age or evidence of heterozygous FH in both parents |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | Initial: 6 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **KALYDECO**

### **Products Affected**

* KALYDECO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of cystic fibrosis (CF) and the patient has 1 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **KISQALI**

### **Products Affected**

* KISQALI (200 MG DOSE)
* KISQALI (400 MG DOSE)
* KISQALI (600 MG DOSE)

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **KISQALI FEMARA**

### **Products Affected**

* KISQALI FEMARA (400 MG DOSE)
* KISQALI FEMARA (600 MG DOSE)
* KISQALI FEMARA(200 MG DOSE)

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **KORLYM**

### **Products Affected**

* KORLYM

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) pregnancy, B.) coadministration with simvastatin, lovastatin, or CYP3A substrates with narrow therapeutic ranges, C.) concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses, D.) history of unexplained vaginal bleeding, E.) endometrial hyperplasia with atypia or endometrial carcinoma |
| **Required Medical Information** | Diagnosis of endogenous Cushing syndrome in patients with type 2 diabetes mellitus or glucose intolerance and must meet all of the following 1.) Used to control hyperglycemia secondary to hypercortisolism, and 2.) Patient has failed or is not a candidate for surgery |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an endocrinologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **KOSELUGO**

### **Products Affected**

* KOSELUGO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of neurofibromatosis type 1 (NF1) in a patient who has symptomatic, inoperable plexiform neurofibromas (PN) |
| **Age Restrictions** | 2 years of age to 17 years of age |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **KYNMOBI**

### **Products Affected**

* KYNMOBI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Concurrent use with 5-HT(3) receptor antagonists (e.g. ondansetron, granisetron, dolasetron, palonosetron, alosetron etc.) |
| **Required Medical Information** | Diagnosis of Parkinson's disease (PD) and patient is experiencing acute intermittent hypomobility (defined as off episodes characterized by muscle stiffness, slow movements, or difficulty starting movements) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LAPATINIB**

### **Products Affected**

* *lapatinib ditosylate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of advanced or metastatic breast cancer with tumors that overexpress human epidermal growth factor receptor 2 (HER2) AND meets one of the following A.) Used in combination with capecitabine in a patient who has received prior therapy including an anthracycline, a taxane, and trastuzumab, OR B.) Used in combination with letrozole in a postmenopausal female for whom hormonal therapy is indicated |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LENALIDOMIDE**

### **Products Affected**

* *lenalidomide oral capsule 10 mg, 15 mg, 25 mg, 5 mg*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Multiple myeloma and medication will be used in combination with dexamethasone, B.) Autologous hematopoietic stem-cell transplantation (HSCT) in multiple myeloma patients, C.) Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality or without additional cytogenetic abnormalities, D.) Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, E.) Follicular lymphoma and used in combination with rituximab, or F.) Marginal zone lymphoma and used in combination with rituximab |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LENVIMA**

### **Products Affected**

* LENVIMA (10 MG DAILY DOSE)
* LENVIMA (12 MG DAILY DOSE)
* LENVIMA (14 MG DAILY DOSE)
* LENVIMA (18 MG DAILY DOSE)
* LENVIMA (20 MG DAILY DOSE)
* LENVIMA (24 MG DAILY DOSE)
* LENVIMA (4 MG DAILY DOSE)
* LENVIMA (8 MG DAILY DOSE)

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, B.) Advanced renal cell carcinoma, in combination with everolimus, following one prior anti-angiogenic therapy, C.) Unresectable hepatocellular carcinoma, first-line therapy, D.) Advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, in combination with pembrolizumab, when disease has progressed following prior systemic therapy and patient is not a candidate for curative surgery or radiation, or E.) Advanced renal cell carcinoma, in combination with pembrolizumab and used as first-line therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LEUKINE**

### **Products Affected**

* LEUKINE INJECTION SOLUTION RECONSTITUTED

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Patient has undergone allogeneic or autologous bone marrow transplant (BMT) and engraftment is delayed or failed, B.) Patient is undergoing autologous peripheral-blood progenitor cell transplant to mobilize progenitor cells for collection by leukapheresis, C.) Medication will be used for myeloid reconstitution after an autologous or allogeneic BMT, D.) Patient has acute myeloid leukemia and administration will be after completion of induction chemotherapy, E.) Hematopoietic subsyndrome of acute radiation syndrome (H-ARS) or F.) Autologous peripheral blood stem cell transplant, Following myeloablative chemotherapy. |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LEUPROLIDE**

### **Products Affected**

* ELIGARD
* *leuprolide acetate injection*
* LUPRON DEPOT (1-MONTH)
* LUPRON DEPOT (3-MONTH)
* LUPRON DEPOT (4-MONTH)
* LUPRON DEPOT (6-MONTH)

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Advanced or metastatic prostate cancer and patient has failed or is intolerant to Eligard (7.5 mg 1-month, 22.5 mg 3-month, 30 mg 4-month, & 45 mg 6-month depots only), B.) Endometriosis (3.75 mg 1-month & 11.25 mg 3-month depots only), C.) Anemia due to uterine leiomyomata (Fibroids) (3.75 mg 1-month &11.25 mg 3-month depots only) and patient is preoperative, or D.) Central precocious puberty (idiopathic or neurogenic) in children |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LINEZOLID**

### **Products Affected**

* *linezolid intravenous solution 600 mg/300ml*
* *linezolid oral*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant use of an MAOI, or B.) Use within 14 days of discontinuing an MAOI |
| **Required Medical Information** | Diagnosis of one of the following A.) Community acquired pneumonia, B.) Hospital-acquired pneumonia, C.) Vancomycin-resistant Enterococcus faecium infection, D.) Complicated skin and skin structure infections, or E.) Uncomplicated skin and skin structure infections |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 1 month |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LONSURF**

### **Products Affected**

* LONSURF

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Metastatic colorectal cancer, previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based regimens, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy, or B.) Metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan and if appropriate, HER2/neu-targeted therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LORBRENA**

### **Products Affected**

* LORBRENA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Concomitant use with strong CYP3A4 inducers |
| **Required Medical Information** | Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LUMAKRAS**

### **Products Affected**

* LUMAKRAS

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test and patient has received at least one prior systemic therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LUPKYNIS**

### **Products Affected**

* LUPKYNIS

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) |
| **Required Medical Information** | Initial: Diagnosis of systemic lupus erythematosus (SLE) with active lupus nephritis (LN) Classes III, IV, V (alone or in combination), and all of the following: 1.) Baseline renal function of 45 mL/min/1.73 m2 or greater, 2.) Will be used in combination with a background immunosuppressive therapy regimen (e.g. mycophenolate, oral steroids, etc). Renewal: Improvement in urine protein to creatinine ratio (UPCR) (i.e. less than or equal to 0.5 mg/mg) AND estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m2 or greater, or no confirmed decrease from baseline in eGFR of greater than 20% |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a rheumatologist or nephrologist |
| **Coverage Duration** | Initial: 12 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **LYNPARZA**

### **Products Affected**

* LYNPARZA ORAL TABLET

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **MATULANE**

### **Products Affected**

* MATULANE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Inadequate marrow reserve |
| **Required Medical Information** | Diagnosis of Hodgkin's Disease, Stages III and IV and used in combination with other anticancer drugs |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **MAYZENT**

### **Products Affected**

* MAYZENT
* MAYZENT STARTER PACK

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) CYP2C9\*3/\*3 genotype, B.) In the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, Class III-IV heart failure, or C.) Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker |
| **Required Medical Information** | Diagnosis of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease and the following A.) Patients with relapsing forms of multiple sclerosis have history of/or contraindication to Avonex, Betaseron, Glatiramer, Gilenya, or Dimethyl Fumarate |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **MEKINIST**

### **Products Affected**

* MEKINIST

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | Pending CMS Review |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **MEKTOVI**

### **Products Affected**

* MEKTOVI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of unresectable or metastatic malignant melanoma with documented BRAF V600E or V600K mutation as detected by an FDA approved test AND used in combination with encorafenib |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **METHOXSALEN**

### **Products Affected**

* *methoxsalen rapid*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Aphakia, B.) Melanoma or a history of melanoma, C.) Invasive squamous cell carcinomas, or D.) History of a light sensitive disease/skin photosensitivity disorder such systemic lupus erythematosus (SLE), porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum or albinism |
| **Required Medical Information** | Diagnosis of one of the following A.) Psoriasis, or B.) Vitiligo |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist, immunologist, or dermatologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **MIGLUSTAT**

### **Products Affected**

* *miglustat*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of mild to moderate type 1 Gaucher disease and patient is not a candidate for enzyme replacement therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **MS INTERFERONS**

### **Products Affected**

* AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
* AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT
* BETASERON SUBCUTANEOUS KIT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **NATPARA**

### **Products Affected**

* NATPARA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of hypoparathyroidism and used to control hypocalcemia |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **NERLYNX**

### **Products Affected**

* NERLYNX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Early stage HER2-positive breast cancer and used following adjuvant trastuzumab therapy, or B.) Advanced or metastatic HER2-positive breast cancer, used in combination with capecitabine, AND patient has received 2 or more prior anti-HER2-based regimens in the metastatic setting |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **NINLARO**

### **Products Affected**

* NINLARO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of multiple myeloma, used in combination with lenalidomide and dexamethasone, AND patient has history of at least 1 prior therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **NITISINONE**

### **Products Affected**

* *nitisinone*
* ORFADIN ORAL CAPSULE 20 MG
* ORFADIN ORAL SUSPENSION

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of hereditary tyrosinemia type 1 |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **NUBEQA**

### **Products Affected**

* NUBEQA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or urologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **NUCALA**

### **Products Affected**

* NUCALA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Severe asthma with eosinophilic phenotype, B.) Eosinophilic granulomatosis with polyangiitis (EGPA), C.) Hypereosinophilic syndrome lasting at least 6 months without an identifiable non-hematologic secondary cause, or D.) Chronic rhinosinusitis with nasal polyps and used as an adjunct treatment |
| **Age Restrictions** | 6 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **NUEDEXTA**

### **Products Affected**

* NUEDEXTA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) History of prolonged QT interval, congenital long QT syndrome or Torsades de pointes, B.) Heart failure, C.) Complete AV block without an implanted pacemaker or high risk of complete AV block, D.) Concomitant use with quinidine, quinine, mefloquine, or drugs that prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine, pimozide), E.) Concomitant use with MAOIs or within 14 days of MAOI therapy, F.) History of quinine-, mefloquine-, or quinidine-induced thrombocytopenia, bone marrow depression, or lupus-like syndrome |
| **Required Medical Information** | Diagnosis of pseudobulbar affect |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **OCTREOTIDE**

### **Products Affected**

* *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Acromegaly and patient has inadequate response to or is ineligible for surgery, radiation, or bromocriptine mesylate, or B.) Metastatic carcinoid syndrome, or C.) Vasoactive intestinal peptide-secreting tumors (VIPomas) with associated diarrhea |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ODOMZO**

### **Products Affected**

* ODOMZO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of locally advanced basal cell carcinoma of the skin and one of the following A.) Cancer has recurred following surgery or radiation therapy, B.) Patient is not a candidate for surgery or radiation therapy. |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **OFEV**

### **Products Affected**

* OFEV

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Idiopathic pulmonary fibrosis (IPF), B.) Systemic sclerosis-associated interstitial lung disease (ILD), or C.) Chronic fibrosing interstitial lung disease with a progressive phenotype |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a pulmonologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ONUREG**

### **Products Affected**

* ONUREG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of acute myeloid leukemia (AML) used in maintenance treatment for adult patients who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **OPSUMIT**

### **Products Affected**

* OPSUMIT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of pulmonary arterial hypertension (WHO Group I), confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e. g., patient is frail, elderly, etc.) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a cardiologist or pulmonologist |
| **Coverage Duration** | Initial: 6 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ORGOVYX**

### **Products Affected**

* ORGOVYX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of advanced prostate cancer |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or urologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ORKAMBI**

### **Products Affected**

* ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG
* ORKAMBI ORAL TABLET

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of cystic fibrosis (CF) with documented homozygous F508del mutation confirmed by FDA-approved CF mutation test |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **OSPHENA**

### **Products Affected**

* OSPHENA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Undiagnosed abnormal genital bleeding, B.) Known or suspected estrogen-dependent neoplasia, C.) Active deep vein thrombosis (DVT), pulmonary embolism (PE), or a history of these conditions, D.) Active arterial thromboembolic disease (e.g. stroke, myocardial infarction) or a history of these conditions, or E.) Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause, or B.) Moderate to severe vaginal dryness due to vulvar and vaginal atrophy associated with menopause |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **OXANDROLONE**

### **Products Affected**

* *oxandrolone oral*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Known or suspected carcinoma of the prostate or breast in males, B.) Carcinoma of the breast in females with hypercalcemia, C.) Pregnancy, D.) Nephrosis or nephrotic phase of nephritis, E.) Hypercalcemia |
| **Required Medical Information** | Diagnosis of one of the following A.) Bone pain associated with osteoporosis, B.) Protein catabolism associated with chronic corticosteroid administration, or C.) Used as adjunctive therapy to promote weight gain after weight loss associated with one of the following 1.) Extensive surgery, 2.) Chronic infections, 3.) Severe trauma, or 4.) Failure to gain or maintain at least 90% of ideal body weight without definite pathophysiologic reasons |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 3 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PANRETIN**

### **Products Affected**

* PANRETIN

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of AIDS-related Kaposi's sarcoma and both of the following 1.) Used to treat cutaneous lesions, and 2.) Systemic anti-Kaposi's Sarcoma therapy is not indicated (e.g., patient does not have more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or HIV specialist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PEGYLATED INTERFERON**

### **Products Affected**

* PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
* PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Autoimmune hepatitis, B.) Hepatic decompensation (Child-Pugh score greater than 6 (Class B and C) in cirrhotic patients before treatment, OR hepatic decompensation (Child-Pugh score greater than or equal to 6) in cirrhotic patients co-infected with hepatitis C and HIV before treatment, C.) Hypersensitivity reactions, including urticaria, bronchoconstriction, anaphylaxis, or Stevens-Johnson syndrome to alfa interferons or any component of the product, or D.) Pregnancy with concomitant ribavirin use |
| **Required Medical Information** | Diagnosis of one of the following A.) Chronic hepatitis B infection, or B.) Chronic hepatitis C and required criteria will be applied consistent with current AASLD-IDSA guidance with compensated liver disease |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PEMAZYRE**

### **Products Affected**

* PEMAZYRE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist, gastroenterologist, or hepatologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PENICILLAMINE**

### **Products Affected**

* *penicillamine oral tablet*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Breastfeeding, B.) During Pregnancy (except for treatment of Wilson's disease), C.) Hypersensitivity to penicillamine products, D.) Penicillamine-related aplastic anemia/agranulocytosis, E.) Rheumatoid arthritis patients with history or evidence of renal insufficiency |
| **Required Medical Information** | Diagnosis of one of the following A.) Cystinuria, B.) Rheumatoid arthritis, or C.) Wilson's disease |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PIQRAY**

### **Products Affected**

* PIQRAY (200 MG DAILY DOSE)
* PIQRAY (250 MG DAILY DOSE)
* PIQRAY (300 MG DAILY DOSE)

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of hormone receptor (HR) positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer and must meet all of the following 1.) Used in combination with fulvestrant, 2.) Disease has progressed on or after an endocrine-based regimen, and 3.) Patient is a male or postmenopausal female |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PIRFENIDONE**

### **Products Affected**

* *pirfenidone oral tablet 267 mg, 801 mg*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of idiopathic pulmonary fibrosis |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a pulmonologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **POMALYST**

### **Products Affected**

* POMALYST

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) AIDS-related Kaposi sarcoma and patient has failure on highly active antiretroviral therapy (HAART), B.) Kaposi sarcoma in HIV-negative adults, or C.) Multiple myeloma and in combination with dexamethasone in adults who have received at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and have demonstrated disease progression on or within 60 days of completion of the last therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **POSACONAZOLE**

### **Products Affected**

* NOXAFIL ORAL SUSPENSION
* *posaconazole*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant treatment with sirolimus, B.) Concomitant use of CYP3A4 substrates that prolong QT interval (pimozide, quinidine), C.) Concomitant use of HMG-CoA Reductase inhibitors primarily metabolized through CYP3A4, or D.) Concomitant use of ergot alkaloids |
| **Required Medical Information** | Diagnosis of one of the following A.) Oropharyngeal candidiasis, B.) Patient is severely immunocompromised and requires prophylaxis of invasive aspergillosis or candidiasis due to high risk of infection, or C.) Invasive aspergillosis |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 weeks |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PREVYMIS**

### **Products Affected**

* PREVYMIS ORAL

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant use with pimozide or ergot alkaloids (ergotamine, dihydroergotamine), B.) Concomitant use with pitavastatin or simvastatin when coadministered with cyclosporine |
| **Required Medical Information** | Must meet both of the following 1.) Patient is CMV-seropositive (R+) and 2.) Patient is receiving an allogeneic hematopoietic stem cell transplant (HSCT) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 6 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PROMACTA**

### **Products Affected**

* PROMACTA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Chronic idiopathic thrombocytopenic purpura (ITP), B.) Chronic hepatitis C infection associated thrombocytopenia, or C.) Severe aplastic anemia with insufficient response to immunosuppressive therapy or in combination with standard immunosuppressive therapy |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **QINLOCK**

### **Products Affected**

* QINLOCK

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of advanced gastrointestinal stromal tumor (GIST) and patient has received prior treatment with 3 or more kinase inhibitors, including imatinib |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **QUININE SULFATE**

### **Products Affected**

* *quinine sulfate oral*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Prolongation of QT interval, B.) Glucose-6-phosphate dehydrogenase deficiency, C.) Myasthenia gravis, D.) Known hypersensitivity to mefloquine or quinidine, E.) Optic neuritis, F.) Diagnosis of Blackwater fever, G.) Use solely for treatment or prevention of nocturnal leg cramps |
| **Required Medical Information** | Diagnosis of one of the following A.) uncomplicated Plasmodium falciparum malaria, B.) uncomplicated Plasmodium vivax malaria, or C.) babesiosis |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 1 month |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **RAVICTI**

### **Products Affected**

* RAVICTI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of urea cycle disorders |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **REGRANEX**

### **Products Affected**

* REGRANEX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Known neoplasm at the site of application |
| **Required Medical Information** | Diagnosis of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply |
| **Age Restrictions** | 16 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **REPATHA**

### **Products Affected**

* REPATHA
* REPATHA PUSHTRONEX SYSTEM
* REPATHA SURECLICK

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH), B.) homozygous familial hypercholesterolemia, C.) established cardiovascular disease and myocardial infarction prophylaxis, stroke prophylaxis, or coronary revascularization prophylaxis is required, or D.) clinical atherosclerotic cardiovascular disease (CVD) as defined as one of the following 1.) acute coronary syndrome, 2.) history of myocardial infarction, 3.) stable/unstable angina, 4.) coronary or other arterial revascularization, 5.) stroke, 6.) transient ischemic stroke (TIA), or 7.) peripheral arterial disease presumed to be atherosclerotic region |
| **Age Restrictions** | 10 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | Initial: 3 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **RETEVMO**

### **Products Affected**

* RETEVMO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Advanced or metastatic RET-mutant medullary thyroid cancer (MTC) in patients who require systemic therapy, B.) Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), or C.) Advanced or metastatic RET fusion-positive thyroid cancer in patients who require systemic therapy and are refractory to radioactive iodine, if appropriate |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **REVLIMID**

### **Products Affected**

* REVLIMID ORAL CAPSULE 2.5 MG, 20 MG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Multiple myeloma and medication will be used in combination with dexamethasone, B.) Autologous hematopoietic stem-cell transplantation (HSCT) in multiple myeloma patients, C.) Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality or without additional cytogenetic abnormalities, D.) Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, E.) Follicular lymphoma and used in combination with rituximab, or F.) Marginal zone lymphoma and used in combination with rituximab |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **REZUROCK**

### **Products Affected**

* REZUROCK

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of chronic graft-vs-host disease and patient has failed at least 2 prior lines of systemic therapy. |
| **Age Restrictions** | 12 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **RILUZOLE**

### **Products Affected**

* *riluzole*
* TIGLUTIK

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of amyotrophic lateral sclerosis (ALS) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **RINVOQ**

### **Products Affected**

* RINVOQ

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Active psoriatic arthritis, C.) Moderate to severe atopic dermatitis and patient has trial/failure, contraindication, or intolerance to two of the following 1.) Topical corticosteroid and/or 2.) Topical calcineurin inhibitor, D.) Moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers, or E.) Active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | Screening for latent tuberculosis infection is required prior to initiation of treatment |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ROZLYTREK**

### **Products Affected**

* ROZLYTREK

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) ROS1-positive metastatic non-small cell lung cancer (NSCLC), or B.) Solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy |
| **Age Restrictions** | 12 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **RUBRACA**

### **Products Affected**

* RUBRACA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by an FDA-approved test and patient has been treated with 2 or more prior lines of chemotherapy, B.) Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, used as maintenance treatment, and patient is in complete or partial response to platinum-based chemotherapy, or C.) Deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer and patient has been treated with androgen receptor-directed therapy and a taxane-based chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **RYDAPT**

### **Products Affected**

* RYDAPT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) treatment naive FLT3 mutation-positive acute myelogenous leukemia (AML) and must be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation therapy, or B.) systemic mastocytosis or mast cell leukemia |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SAPROPTERIN**

### **Products Affected**

* *sapropterin dihydrochloride oral packet*
* *sapropterin dihydrochloride oral tablet*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of hyperphenylalaninemia (HPA) caused by tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | Initial: 2 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SCEMBLIX**

### **Products Affected**

* SCEMBLIX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), or B.) Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SIGNIFOR**

### **Products Affected**

* SIGNIFOR

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of Cushing disease and patient has had inadequate response to or is not a candidate for surgery. For renewal: Documentation of a clinically meaningful reduction in 24-hour urinary free cortisol (UFC) levels or improvement in signs or symptoms of the disease |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | Initial: 6 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SILDENAFIL**

### **Products Affected**

* *sildenafil citrate oral tablet 20 mg*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Nitrate therapy, including intermittent use, B.) Concomitant use with riocguat or other guanylate cyclase stimulators, C.) Concomitant use with HIV protease inhibitors or elvitegravir/cobicistat/tenofovir/emtricitabine |
| **Required Medical Information** | Diagnosis of pulmonary arterial hypertension (WHO Group I), confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a cardiologist or pulmonologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SIRTURO**

### **Products Affected**

* SIRTURO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Must meet all of the following 1.) Diagnosis of pulmonary multidrug resistant tuberculosis (MDR-TB) and 2.) Used in combination with at least 3 other antibiotics for the treatment of pulmonary multi-drug resistant tuberculosis |
| **Age Restrictions** | 5 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an infectious disease specialist |
| **Coverage Duration** | 24 weeks |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SKYRIZI**

### **Products Affected**

* SKYRIZI (150 MG DOSE)
* SKYRIZI PEN
* SKYRIZI SUBCUTANEOUS

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | Screening for latent tuberculosis infection is required prior to initiation of treatment |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SOLTAMOX**

### **Products Affected**

* SOLTAMOX

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant coumarin-type anticoagulant therapy, B.) history of thromboembolic disease such as DVT or PE |
| **Required Medical Information** | Diagnosis of breast cancer and documentation of inability to swallow tablet formulation |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SOMAVERT**

### **Products Affected**

* SOMAVERT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of acromegaly and patient has had an inadequate response to or is ineligible for surgery or radiation therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an endocrinologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SORAFENIB**

### **Products Affected**

* *sorafenib tosylate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Squamous cell lung cancer being treated with carboplatin and paclitaxel |
| **Required Medical Information** | Diagnosis of one of the following A.) Advanced renal cell carcinoma, B.) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment, or C.) Unresectable hepatocellular carcinoma |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SPRYCEL**

### **Products Affected**

* SPRYCEL

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, B.) Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, C.) Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, or D.) Newly diagnosed Ph+ ALL in combination with chemotherapy |
| **Age Restrictions** | 1 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **STELARA**

### **Products Affected**

* STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
* STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Moderate to severely active Crohn disease, B.) Moderate to severe plaque psoriasis, C.) Active psoriatic arthritis, or D.) Moderate to severe active ulcerative colitis |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | Screening for latent tuberculosis infection is required prior to initiation of treatment |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **STIVARGA**

### **Products Affected**

* STIVARGA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Metastatic colorectal cancer in patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan containing chemotherapy, anti-VEGF therapy, and if RAS wild type, anti-EGFR therapy, B.) Liver carcinoma in patients previously treated with sorafenib, or C.) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with imatinib and sunitinib |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SUNITINIB**

### **Products Affected**

* *sunitinib malate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, B.) Pancreatic neuroendocrine tumors in a patient with unresectable locally advanced or metastatic disease, C.) Advanced renal cell carcinoma, or D.) Renal cell carcinoma and used as adjuvant therapy following nephrectomy in patients who are at high risk for recurrence |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SUNOSI**

### **Products Affected**

* SUNOSI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant use of an MAOI, or B.) Use within 14 days of discontinuing an MAOI |
| **Required Medical Information** | Diagnosis of one of the following A.) narcolepsy with excessive daytime drowsiness and has trial of/or contraindication to modafinil or armodafinil, or B.) obstructive sleep apnea (OSA) with excessive daytime drowsiness and has trial of/or contraindication to modafinil or armodafinil |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SYMDEKO**

### **Products Affected**

* SYMDEKO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of cystic fibrosis (CF) and must meet one of the following 1.) Patient is homozygous for the F508del mutation, or 2.) Patient has at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor verified by an FDA-cleared CF mutation test |
| **Age Restrictions** | 6 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation |
| **Coverage Duration** | Initial: 6 months, Renewal: 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SYMLIN**

### **Products Affected**

* SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
* SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Confirmed diagnosis of gastroparesis, B.) Hypoglycemia unawareness |
| **Required Medical Information** | Diagnosis of type 1 or type 2 diabetes mellitus and patient uses mealtime insulin therapy and has failed to achieve desired glucose control |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SYNAREL**

### **Products Affected**

* SYNAREL

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) pregnancy, B.) breastfeeding, C.) undiagnosed abnormal vaginal bleeding |
| **Required Medical Information** | Diagnosis of one of the following A.) Central precocious puberty, or B.) Endometriosis |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **SYNRIBO**

### **Products Affected**

* SYNRIBO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of chronic or accelerated phase chronic myeloid leukemia (CML) and patient has tried and failed or has a contraindication or intolerance to at least 2 tyrosine kinase inhibitors |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TABRECTA**

### **Products Affected**

* TABRECTA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TAFINLAR**

### **Products Affected**

* TAFINLAR

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | Pending CMS Review |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TAGRISSO**

### **Products Affected**

* TAGRISSO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R mutation and used as first line therapy, B.) Metastatic non-small cell lung cancer with T790M EGFR mutation (as confirmed by an FDA-approved test) AND whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy, or C.) Non-small cell lung cancer (NSCLC) with tumor epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as confirmed by an FDA-approved test) AND patient requires adjuvant therapy after tumor resection |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TAKHZYRO**

### **Products Affected**

* TAKHZYRO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following and used as routine prophylaxis A.) Hereditary angioedema (HAE) with C1 inhibitor deficiency (Type 1) confirmed by laboratory testing, or B.) HAE with C1 inhibitor dysfunction (Type 2) confirmed by laboratory testing, or C.) HAE with normal C1 inhibitor (Type 3) confirmed by laboratory testing and one of the following 1.) Positive test for an F12, angiopoietin-1, or plasminogen gene mutation, or 2.) Family history of angioedema and the angioedema was refractory to a trial of an antihistamine for at least one month |
| **Age Restrictions** | 12 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a hematologist, immunologist, or allergist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TALZENNA**

### **Products Affected**

* TALZENNA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TASIGNA**

### **Products Affected**

* TASIGNA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Long QT syndrome, B.) Uncorrected hypokalemia, C.) Uncorrected hypomagnesemia |
| **Required Medical Information** | Diagnosis of one of the following A.) Newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML), B.) Chronic phase or accelerated phase Philadelphia chromosome-positive CML in a patient with resistance or intolerance to prior therapy that included imatinib, or C.) Chronic phase Philadelphia chromosome-positive CML in a patient with resistance or intolerance to prior tyrosine-kinase inhibitor therapy |
| **Age Restrictions** | 1 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TAVNEOS**

### **Products Affected**

* TAVNEOS

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) and both of the following apply 1.) Used as adjunctive treatment, and 2.) Used in combination with standard therapy including glucocorticoids |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TAZAROTENE**

### **Products Affected**

* *tazarotene external cream*
* TAZORAC EXTERNAL CREAM 0.05 %
* TAZORAC EXTERNAL GEL

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Acne vulgaris and patient has trial with at least one generic topical acne product, or B.) Stable moderate to severe plaque psoriasis with 20% or less body surface area involvement and patient has trial with at least one other topical psoriasis product (e.g., medium to high potency corticosteroid and/or vitamin D analogs) |
| **Age Restrictions** | 12 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TAZVERIK**

### **Products Affected**

* TAZVERIK

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Metastatic or locally advanced epithelioid sarcoma in patients not eligible for complete resection, B.) Relapsed or refractory follicular lymphoma in patients whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, or C.) Relapsed or refractory follicular lymphoma in patients who have no satisfactory alternative treatment options |
| **Age Restrictions** | 16 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TEGSEDI**

### **Products Affected**

* TEGSEDI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Platelet count less than 100,000 per microliter, B.) Urinary protein to creatinine ratio (UPCR) of 1000 mg/g or higher |
| **Required Medical Information** | Diagnosis of Polyneuropathy of hereditary transthyretin-mediated amyloidosis |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TEPMETKO**

### **Products Affected**

* TEPMETKO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping alterations |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TERIPARATIDE**

### **Products Affected**

* *teriparatide (recombinant)*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Osteoporosis in postmenopausal female patient with high risk for fracture and patient has contraindication or has tried/had inadequate response to a bisphosphonate or Tymlos, B.) Primary or hypogonadal osteoporosis in male patient with high risk for fracture and patient has contraindication or has tried/had inadequate response to a bisphosphonate, or C.) Osteoporosis due to associated sustained systemic glucocorticoid therapy in patient with high risk for fracture and patient has contraindication or has tried/had inadequate response to a bisphosphonate |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | Initial: 12 months, Renewal: 12 months (Maximum 24 month treatment per patient lifetime) |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TETRABENAZINE**

### **Products Affected**

* *tetrabenazine*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Actively suicidal, B.) Untreated or inadequately treated depression, C.) Impaired hepatic function, D.) Concomitant use of monoamine oxidase inhibitors, E.) Concomitant use of reserpine or within 20 days of discontinuing reserpine |
| **Required Medical Information** | Diagnosis of chorea associated with Huntington's disease |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **THALOMID**

### **Products Affected**

* THALOMID

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Multiple myeloma that is newly diagnosed, or B.) Erythema nodosum leprosum (ENL) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or infectious disease specialist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TIBSOVO**

### **Products Affected**

* TIBSOVO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation (as detected by an FDA-approved test), B.) Previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation (as detected by an FDA-approved test.), or C.) Acute myeloid leukemia (newly-diagnosed) with susceptible isocitrate dehydrogenase-1 mutation and meets one of the following: 1.) Patient is 75 years of age or older, or 2.) Patient has comorbidities that preclude intensive induction chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a gastroenterologist, hematologist, hepatologist, or oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TOLVAPTAN**

### **Products Affected**

* *tolvaptan*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD), B.) Urgent need to raise serum sodium acutely, C.) Inability to sense or appropriately respond to thirst, D.) Hypovolemic hyponatremia, E.) Concomitant use of strong CYP 3A Inhibitors (e.g. clarithromycin, ketoconazole, ritonavir), or F.) Anuria |
| **Required Medical Information** | Diagnosis of clinically significant hypervolemic or euvolemic hyponatremia (serum sodium less than 125 mEq/L or less marks hyponatremia that is symptomatic and has resisted correction with fluid restriction), including in patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 1 month |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TOPICAL RETINOIDS**

### **Products Affected**

* *adapalene external cream*
* *adapalene external gel 0.3 %*
* *tretinoin external cream*
* *tretinoin external gel 0.01 %, 0.025 %*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of mild to moderate acne vulgaris |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TOPICAL TESTOSTERONE**

### **Products Affected**

* *testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
* *testosterone transdermal solution*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Carcinoma of the breast (males only), B.) Known or suspected carcinoma of the prostate, C.) Pregnancy |
| **Required Medical Information** | Diagnosis of one of the following A.) Hypogonadotropic hypogonadism, or B.) Primary hypogonadism. Diagnosis of hypogonadism must be confirmed by a low-for-age serum testosterone (total or free) level defined by the normal laboratory reference value |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TOREMIFENE**

### **Products Affected**

* *toremifene citrate*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Acquired or congenital long QT syndrome, B.) Uncorrected hypokalemia, C.) Uncorrected hypomagnesemia |
| **Required Medical Information** | Diagnosis of metastatic breast cancer and patient must have previous inadequate response or intolerance to tamoxifen |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 6 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TRELSTAR**

### **Products Affected**

* TRELSTAR MIXJECT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of advanced prostate cancer and used in palliative treatment |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TRIENTINE**

### **Products Affected**

* *trientine hcl*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of Wilson's disease in patients that are intolerant to penicillamine |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TRIKAFTA**

### **Products Affected**

* TRIKAFTA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of cystic fibrosis (CF) and patient has at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene verified by an FDA-cleared CF mutation test |
| **Age Restrictions** | 6 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TRUSELTIQ**

### **Products Affected**

* TRUSELTIQ (100MG DAILY DOSE)
* TRUSELTIQ (125MG DAILY DOSE)
* TRUSELTIQ (50MG DAILY DOSE)
* TRUSELTIQ (75MG DAILY DOSE)

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a gastroenterologist, hepatologist, or oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TUKYSA**

### **Products Affected**

* TUKYSA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of advanced unresectable or metastatic HER2-positive breast cancer (including brain metastases) in patients who have received one or more prior anti-HER2-based regimens in the metastatic setting and drug is being used in combination with trastuzumab and capecitabine |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TURALIO**

### **Products Affected**

* TURALIO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **TYMLOS**

### **Products Affected**

* TYMLOS

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of postmenopausal osteoporosis and one of the following A.) osteoporotic fracture or multiple risk factors for fracture, or B.) previous trial of/or contraindication to bisphosphonate |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | Initial: 12 months, Renewal: 12 months (Maximum 24 month treatment per patient lifetime) |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **UBRELVY**

### **Products Affected**

* UBRELVY

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) |
| **Required Medical Information** | Diagnosis of migraine disorder with or without aura and patient has documented trial, inadequate response, or contraindication to at least 1 generic formulary triptan |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VALCHLOR**

### **Products Affected**

* VALCHLOR

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of cutaneous T-cell lymphoma (stage IA and IB mycosis fungoides-type) and patient has received prior skin-directed therapy (e.g. Topical corticosteroids, phototherapy, or topical nitrogen mustard) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VENCLEXTA**

### **Products Affected**

* VENCLEXTA
* VENCLEXTA STARTING PACK

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Concomitant use with strong CYP3A inhibitor during the initial and titration phase in patients with CLL or SLL |
| **Required Medical Information** | Diagnosis of one of the following A.) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), or B.) Newly-diagnosed acute myeloid leukemia (AML) and used in combination with azacitidine, decitabine or low-dose cytarabine in patients 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VERQUVO**

### **Products Affected**

* VERQUVO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant use of other soluble guanylate cyclase (sGC) stimulators, or B.) Pregnancy |
| **Required Medical Information** | Diagnosis of chronic heart failure (HF), NYHA Class II to IV and all of the following 1.) Left ventricular ejection fraction less than 45%, 2.) Previous hospitalization for HF within 6 months or outpatient IV diuretic treatment for HF within 3 months |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with a cardiologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VERZENIO**

### **Products Affected**

* VERZENIO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer and ALL of the following: 1.) Patient is at high risk of recurrence, 2.) Ki-67 score 20% or greater as determined by an FDA approved test, and 3.) Requested drug will be used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment, OR B.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and one of the following 1.) Used in combination with fulvestrant in a patient with disease progression following endocrine therapy, 2.) Used as monotherapy in a patient with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting, or 3.) For postmenopausal women, and men, used as initial endocrine-based treatment in combination with an aromatase inhibitor |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VIGABATRIN**

### **Products Affected**

* *vigabatrin*
* VIGADRONE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Infantile spasms, or B.) Refractory complex partial seizures and the drug is being used as adjunctive therapy in patients who have responded inadequately to two alternative treatments |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with a neurologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VIJOICE**

### **Products Affected**

* VIJOICE

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) in patients who require systemic therapy |
| **Age Restrictions** | 2 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VITRAKVI**

### **Products Affected**

* VITRAKVI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of metastatic or surgically unresectable neurotrophic receptor tyrosine kinase (NTRK) gene fusion positive solid tumors without a known acquired resistance mutation and used in patients with unsatisfactory alternative treatments or who have progressed following treatment |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VIZIMPRO**

### **Products Affected**

* VIZIMPRO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of metastatic non-small cell lung cancer with confirmed epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VONJO**

### **Products Affected**

* VONJO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of intermediate or high-risk primary or secondary myelofibrosis in adults AND a platelet count less than 50 X 10(9)/L |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VORICONAZOLE**

### **Products Affected**

* *voriconazole intravenous*
* *voriconazole oral*

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant use of carbamazepine, CYP3A4 substrates (e.g., terfenadine, astemizole, cisapride, pimozide, or quinidine), B.) Concomitant use with high-dose ritonavir (400mg every 12 hours), C.) Concomitant use with ergot alkaloids, D.) Concomitant use with long-acting barbiturates, E.) Conc0mitant use with rifabutin or rifampin, F.) Concomitant use with sirolimus, or G.) Concomitant use with efavirenz at standard doses of 400mg/day or higher |
| **Required Medical Information** | Diagnosis of one of the following A.) Invasive aspergillosis, B.) Candidemia, C.) Esophageal Candidiasis, D.) Invasive candidiasis of the skin and abdomen, kidney, bladder wall, and wounds, or E.) Serious fungal infection due to Scedosporium apiospermum or Fusarium species |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an infectious disease specialist |
| **Coverage Duration** | 6 months |
| **Other Criteria** | IV formulation: B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **VOTRIENT**

### **Products Affected**

* VOTRIENT

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Advanced renal cell carcinoma, or B.) Advanced soft tissue sarcoma and patient received at least one prior chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **WELIREG**

### **Products Affected**

* WELIREG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of von Hippel-Lindau (VHL) disease and therapy is required for any of the following disease associated tumors that do not require immediate surgery A.) Renal cell carcinoma (RCC), B.) Central nervous system (CNS) hemangioblastoma, or C.) Pancreatic neuroendocrine tumor (pNET) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **XALKORI**

### **Products Affected**

* XALKORI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **XGEVA**

### **Products Affected**

* XGEVA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Hypocalcemia (calcium less than 8.0 mg/dL) |
| **Required Medical Information** | Diagnosis of one of the following A.) Bone metastases from a solid tumor and used for the prevention of skeletal related events, B.) Multiple myeloma and used for the prevention of skeletal related events, C.) Hypercalcemia of malignancy refractory to bisphosphonate therapy, or D.) Giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **XOLAIR**

### **Products Affected**

* XOLAIR

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Chronic idiopathic urticaria in patients who remain symptomatic despite H1 antihistamine therapy and patient will continue to receive concurrent H1 antihistamine therapy unless contraindicated or not tolerated, B.) Moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms are inadequately controlled with inhaled corticosteroids and an additional controller medication (i.e. long acting beta2-agonist, leukotriene modifier, or sustained-release theophylline) and patient has trial and failure, contraindication, or intolerance to Dupixent or Nucala, or C.) Nasal polyps in patients with inadequate response to nasal corticosteroids, requested drug will be used as adjunctive treatment, and patient has trial and failure, contraindication, or intolerance to Dupixent |
| **Age Restrictions** | 6 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | B vs D determination required per CMS guidance |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **XOSPATA**

### **Products Affected**

* XOSPATA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **XPOVIO**

### **Products Affected**

* XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
* XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
* XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
* XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
* XPOVIO (60 MG TWICE WEEKLY)
* XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
* XPOVIO (80 MG TWICE WEEKLY)

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Relapsed or refractory multiple myeloma being used in combination with dexamethasone in a patient who has received at least 4 prior therapies and is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody, B.) Multiple myeloma being used in combination with bortezomib and dexamethasone in a patient who has received at least 1 prior therapy, C.) Relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, or D.) Relapsed or refractory DLBCL arising from follicular lymphoma and patient has received at least 2 lines of systemic therapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **XTANDI**

### **Products Affected**

* XTANDI

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Castration-resistant prostate cancer, or B.) Metastatic, castration-sensitive prostate cancer |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or urologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **XYREM**

### **Products Affected**

* XYREM

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant treatment with sedative hypnotic agents, B.) Succinic semialdehyde dehydrogenase deficiency |
| **Required Medical Information** | Diagnosis of one of the following A.) Narcolepsy with excessive daytime drowsiness and has trial of/or contraindication to a central nervous system (CNS) stimulant drug (e.g., amphetamine, dextroamphetamine, methylphenidate) or a CNS wakefulness promoting drug (e.g., armodafinil, modafinil), or B.) Cataplexy and narcolepsy |
| **Age Restrictions** | 7 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **XYWAV**

### **Products Affected**

* XYWAV

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Any of the following A.) Concomitant treatment with sedative hypnotic agents, B.) Succinic semialdehyde dehydrogenase deficiency |
| **Required Medical Information** | Diagnosis of one of the following A.) Narcolepsy with excessive daytime drowsiness and has trial of/or contraindication to a central nervous system (CNS) stimulant drug (e.g., amphetamine, dextroamphetamine, methylphenidate) or a CNS wakefulness promoting drug (e.g., armodafinil, modafinil), or B.) Cataplexy and narcolepsy, or C.) Idiopathic hypersomnia |
| **Age Restrictions** | 7 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **YONSA**

### **Products Affected**

* YONSA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | Pregnancy |
| **Required Medical Information** | Diagnosis of metastatic, castration-resistant prostate cancer and use in combination with methylprednisolone |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or urologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ZARXIO**

### **Products Affected**

* ZARXIO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Chemotherapy induced febrile neutropenia (prophylaxis), B.) Severe chronic neutropenia, C.) Patient is undergoing autologous peripheral-blood progenitor cell transplant to mobilize progenitor cells for collection by leukapheresis, or D.) Hematopoietic subsyndrome of acute radiation syndrome (H-ARS) |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ZEJULA**

### **Products Affected**

* ZEJULA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and used as maintenance therapy in a patient who is in a complete or partial response to platinum-based chemotherapy, or B.) Advanced ovarian, fallopian tube, or primary peritoneal cancer and patient has been treated with 3 or more prior chemotherapy regimens, and cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability, and disease has progressed more than 6 months after response to the last platinum-based chemotherapy |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ZELBORAF**

### **Products Affected**

* ZELBORAF

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of one of the following A.) Unresectable or metastatic melanoma and patient has positive BRAF-V600E mutation documented by an FDA-approved test, or B.) Erdheim-Chester disease and patient has documented BRAF V600 mutation |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ZIEXTENZO**

### **Products Affected**

* ZIEXTENZO

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of a non-myeloid malignancy and drug is being used as prophylaxis for chemotherapy-induced neutropenia |
| **Age Restrictions** | None |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ZOLINZA**

### **Products Affected**

* ZOLINZA

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of primary cutaneous T-cell lymphoma (CTCL) in patients who have progressive, persistent or recurrent disease on or following two systemic therapies (e.g., bexarotene, romidepsin, etc) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | None |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ZYDELIG**

### **Products Affected**

* ZYDELIG

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | History of toxic epidermal necrosis with any drug |
| **Required Medical Information** | Pending CMS Review |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist or hematologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **ZYKADIA**

### **Products Affected**

* ZYKADIA ORAL TABLET

| **PA Criteria** | **Criteria Details** |
| --- | --- |
| **Exclusion Criteria** | None |
| **Required Medical Information** | Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) |
| **Age Restrictions** | 18 years of age and older |
| **Prescriber Restrictions** | Prescribed by or in consultation with an oncologist |
| **Coverage Duration** | 12 months |
| **Other Criteria** | None |
| **Indications** | All Medically-accepted Indications. |
| **Off-Label Uses** | N/A |
| **Part B Prerequisite** | No |

## **PART B VERSUS PART D**

### **Products Affected**

* ABELCET INTRAVENOUS SUSPENSION 5 MG/ML
* *acetylcysteine inhalation solution 10 %, 20 %*
* *acyclovir sodium intravenous solution 50 mg/ml*
* *albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml*
* AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50 MG
* *amphotericin b intravenous solution reconstituted 50 mg*
* *aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg*
* *azathioprine oral tablet 100 mg, 50 mg, 75 mg*
* *budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml*
* *calcitonin (salmon) nasal solution 200 unit/act*
* *calcitriol oral capsule 0.25 mcg, 0.5 mcg*
* *calcitriol oral solution 1 mcg/ml*
* *cinacalcet hcl oral tablet 30 mg, 60 mg, 90 mg*
* CLINIMIX E/DEXTROSE (2.75/5) INTRAVENOUS SOLUTION 2.75 %
* CLINIMIX E/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 %
* CLINIMIX E/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 %
* CLINIMIX E/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 %
* CLINIMIX E/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 %
* CLINIMIX/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 %
* CLINIMIX/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 %
* CLINIMIX/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 %
* CLINIMIX/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 %
* CLINISOL SF INTRAVENOUS SOLUTION 15 %
* *cromolyn sodium inhalation nebulization solution 20 mg/2ml*
* *cyclophosphamide oral capsule 25 mg, 50 mg*
* *cyclophosphamide oral tablet 25 mg, 50 mg*
* *cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg*
* *cyclosporine modified oral solution 100 mg/ml*
* *cyclosporine oral capsule 100 mg, 25 mg*
* *diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml*
* ENGERIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML, 20 MCG/ML (PREFILLED SYRINGE)
* ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG
* *everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg*
* GENGRAF ORAL CAPSULE 100 MG, 25 MG
* GENGRAF ORAL SOLUTION 100 MG/ML
* *granisetron hcl oral tablet 1 mg*
* IMOVAX RABIES INTRAMUSCULAR INJECTABLE 2.5 UNIT/ML
* INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %
* *ipratropium bromide inhalation solution 0.02 %*
* *ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml*
* ISOLYTE-P IN D5W INTRAVENOUS SOLUTION
* ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION
* *levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/0.5ml, 1.25 mg/3ml*
* *methotrexate sodium (pf) injection solution 50 mg/2ml*
* *methotrexate sodium injection solution 50 mg/2ml*
* *methotrexate sodium oral tablet 2.5 mg*
* *methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg*
* *mycophenolate mofetil oral capsule 250 mg*
* *mycophenolate mofetil oral suspension reconstituted 200 mg/ml*
* *mycophenolate mofetil oral tablet 500 mg*
* *mycophenolate sodium oral tablet delayed release 180 mg, 360 mg*
* NUTRILIPID INTRAVENOUS EMULSION 20 %
* *ondansetron hcl injection solution 4 mg/2ml, 40 mg/20ml*
* *ondansetron hcl oral solution 4 mg/5ml*
* *ondansetron hcl oral tablet 4 mg, 8 mg*
* *ondansetron oral tablet dispersible 4 mg, 8 mg*
* PANZYGA INTRAVENOUS SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML
* *paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg*
* *pentamidine isethionate inhalation solution reconstituted 300 mg*
* PLASMA-LYTE 148 INTRAVENOUS SOLUTION
* PLASMA-LYTE A INTRAVENOUS SOLUTION
* PLENAMINE INTRAVENOUS SOLUTION 15 %
* *prednisolone oral solution 15 mg/5ml*
* *prednisolone sodium phosphate oral solution 10 mg/5ml, 20 mg/5ml, 25 mg/5ml, 6.7 (5 base) mg/5ml*
* *prednisolone sodium phosphate oral tablet dispersible 10 mg, 15 mg, 30 mg*
* PREDNISONE INTENSOL ORAL CONCENTRATE 5 MG/ML
* *prednisone oral solution 5 mg/5ml*
* *prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg*
* *prehevbrio intramuscular suspension 10 mcg/ml*
* PREMASOL INTRAVENOUS SOLUTION 10 %
* PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML
* PROGRAF ORAL PACKET 0.2 MG, 1 MG
* PROSOL INTRAVENOUS SOLUTION 20 %
* PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML
* RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED
* RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 10 MCG/ML (1ML SYRINGE), 40 MCG/ML, 5 MCG/0.5ML, 5 MCG/0.5ML (PREFILLED SYRINGE)
* SANDIMMUNE ORAL SOLUTION 100 MG/ML
* *sirolimus oral solution 1 mg/ml*
* *sirolimus oral tablet 0.5 mg, 1 mg, 2 mg*
* *tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg*
* TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML
* TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION)
* *tobramycin inhalation nebulization solution 300 mg/5ml*
* TPN ELECTROLYTES INTRAVENOUS CONCENTRATE
* TRAVASOL INTRAVENOUS SOLUTION 10 %
* TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG
* TROPHAMINE INTRAVENOUS SOLUTION 10 %
* XATMEP ORAL SOLUTION 2.5 MG/ML

## **Details**

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

**Index**

A

ABELCET INTRAVENOUS SUSPENSION 5 MG/ML 236

abiraterone acetate 1

acetylcysteine inhalation solution 10 %, 20 % 236

acitretin 2

ACTIMMUNE 3

acyclovir sodium intravenous solution 50 mg/ml 236

adapalene external cream 197

adapalene external gel 0.3 % 197

adefovir dipivoxil 72

ADEMPAS 4

albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml 236

ALECENSA 6

alosetron hcl 7

ALUNBRIG 9

AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50 MG 236

ambrisentan 10

amphotericin b intravenous solution reconstituted 50 mg 236

aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg 236

ARCALYST 11

ARIKAYCE 12

aripiprazole 74, 75

armodafinil 31

asenapine maleate 74, 75

AURYXIA 13

AUSTEDO 14

AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 123

AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 123

AYVAKIT 15

azathioprine oral tablet 100 mg, 50 mg, 75 mg 236

B

BALVERSA 16

BARACLUDE ORAL SOLUTION 72

BENLYSTA SUBCUTANEOUS 17

BESREMI 18

BETASERON SUBCUTANEOUS KIT 123

bexarotene external 19

bexarotene oral 20

bosentan 21

BOSULIF 22

BRAFTOVI ORAL CAPSULE 75 MG 23

BRUKINSA 24

budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml 236

C

CABOMETYX 25

calcitonin (salmon) nasal solution 200 unit/act 236

calcitriol oral capsule 0.25 mcg, 0.5 mcg 236

calcitriol oral solution 1 mcg/ml 236

CALQUENCE ORAL CAPSULE 26

CAMZYOS 27

CAPLYTA ORAL CAPSULE 42 MG 74, 75

CAPRELSA 28

carglumic acid oral tablet soluble 29

CAYSTON 30

chlorpromazine hcl oral 74, 75

cinacalcet hcl oral tablet 30 mg, 60 mg, 90 mg 236

CLINIMIX E/DEXTROSE (2.75/5) INTRAVENOUS SOLUTION 2.75 % 236

CLINIMIX E/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 % 236

CLINIMIX E/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 % 236

CLINIMIX E/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 % 236

CLINIMIX E/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 % 236

CLINIMIX/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 % 236

CLINIMIX/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 % 236

CLINIMIX/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 % 236

CLINIMIX/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 % 236

CLINISOL SF INTRAVENOUS SOLUTION 15 % 236

clozapine 74, 75

COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG 32

COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG 32

COMETRIQ (60 MG DAILY DOSE) 32

COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 70

COPIKTRA 33

CORLANOR ORAL TABLET 34

COSENTYX (300 MG DOSE) 35

COSENTYX SENSOREADY (300 MG) 35

COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML 35

COTELLIC 36

cromolyn sodium inhalation nebulization solution 20 mg/2ml 236

cyclophosphamide oral capsule 25 mg, 50 mg 236

cyclophosphamide oral tablet 25 mg, 50 mg 236

cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg 236

cyclosporine modified oral solution 100 mg/ml 236

cyclosporine oral capsule 100 mg, 25 mg 236

CYSTADROPS 38

CYSTAGON 37

CYSTARAN 38

D

dalfampridine er 39

DAURISMO 40

deferasirox granules 41

deferasirox oral tablet 41

deferasirox oral tablet soluble 41

deferiprone 42

DIACOMIT 43

diclofenac sodium external gel 3 % 44

dimethyl fumarate oral 45

dimethyl fumarate starter pack 45

diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml 236

dronabinol 46

droxidopa 47

DUPIXENT 48

E

ELIGARD 110

EMGALITY 49

EMSAM 50

ENBREL MINI 51

ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML 51

ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 51

ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED 51

ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 51

ENDARI 52

ENGERIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML, 20 MCG/ML (PREFILLED SYRINGE) 236

entecavir 72

ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG 236

EPIDIOLEX 53

ERIVEDGE 55

ERLEADA 56

erlotinib hcl 57

ESBRIET ORAL CAPSULE 58

everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg 236

everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg 5

everolimus oral tablet soluble 59

EVRYSDI 60

EXKIVITY 61

F

FANAPT 74, 75

FANAPT TITRATION PACK 74, 75

fentanyl 63

fentanyl citrate buccal lozenge on a handle 62

FERRIPROX ORAL SOLUTION 42

FERRIPROX TWICE-A-DAY 42

FINTEPLA 64

FIRAZYR 79

fluphenazine hcl injection 74, 75

fluphenazine hcl oral 74, 75

FOTIVDA 65

G

GATTEX 66

GAVRETO 67

GENGRAF ORAL CAPSULE 100 MG, 25 MG 236

GENGRAF ORAL SOLUTION 100 MG/ML 236

GILENYA ORAL CAPSULE 0.5 MG 68

GILOTRIF 69

glatiramer acetate 70

granisetron hcl oral tablet 1 mg 236

H

haloperidol lactate 74, 75

haloperidol oral 74, 75

HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML 76, 77

HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 76, 77

HUMIRA PEN-CD/UC/HS STARTER 76, 77

HUMIRA PEN-PEDIATRIC UC START 76, 77

HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML 76, 77

HUMIRA PEN-PSOR/UVEIT STARTER 76, 77

HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML 76, 77

I

IBRANCE 78

icatibant acetate 79

ICLUSIG 80

IDHIFA 81

imatinib mesylate 82

IMBRUVICA ORAL CAPSULE 83

IMBRUVICA ORAL TABLET 83

IMOVAX RABIES INTRAMUSCULAR INJECTABLE 2.5 UNIT/ML 236

INBRIJA 84

INCRELEX 85

INGREZZA 86

INLYTA 88

INQOVI 89

INREBIC 90

INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % 236

INTRON A INJECTION SOLUTION RECONSTITUTED 91, 92

ipratropium bromide inhalation solution 0.02 % 236

ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml 236

IRESSA 93

ISOLYTE-P IN D5W INTRAVENOUS SOLUTION 236

ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION 236

ISTURISA 94

itraconazole oral 95, 96

ivermectin oral 97

J

JAKAFI 98

JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG 99

K

KALYDECO 100

KISQALI (200 MG DOSE) 101

KISQALI (400 MG DOSE) 101

KISQALI (600 MG DOSE) 101

KISQALI FEMARA (400 MG DOSE) 102

KISQALI FEMARA (600 MG DOSE) 102

KISQALI FEMARA(200 MG DOSE) 102

KORLYM 103

KOSELUGO 104

KYNMOBI 105

L

lapatinib ditosylate 106

LATUDA 74, 75

lenalidomide oral capsule 10 mg, 15 mg, 25 mg, 5 mg 107

LENVIMA (10 MG DAILY DOSE) 108

LENVIMA (12 MG DAILY DOSE) 108

LENVIMA (14 MG DAILY DOSE) 108

LENVIMA (18 MG DAILY DOSE) 108

LENVIMA (20 MG DAILY DOSE) 108

LENVIMA (24 MG DAILY DOSE) 108

LENVIMA (4 MG DAILY DOSE) 108

LENVIMA (8 MG DAILY DOSE) 108

LEUKINE INJECTION SOLUTION RECONSTITUTED 109

leuprolide acetate injection 110

levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/0.5ml, 1.25 mg/3ml 237

linezolid intravenous solution 600 mg/300ml 111

linezolid oral 111

LONSURF 112

LORBRENA 113

loxapine succinate oral 74, 75

LUMAKRAS 114

LUPKYNIS 115

LUPRON DEPOT (1-MONTH) 110

LUPRON DEPOT (3-MONTH) 110

LUPRON DEPOT (4-MONTH) 110

LUPRON DEPOT (6-MONTH) 110

LYBALVI 74, 75

LYNPARZA ORAL TABLET 116

M

MATULANE 117

MAVYRET 73

MAYZENT 118

MAYZENT STARTER PACK 118

MEKINIST 119

MEKTOVI 120

methotrexate sodium (pf) injection solution 50 mg/2ml 237

methotrexate sodium injection solution 50 mg/2ml 237

methotrexate sodium oral tablet 2.5 mg 237

methoxsalen rapid 121

methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg 237

miglustat 122

modafinil 31

molindone hcl 74, 75

mycophenolate mofetil oral capsule 250 mg 237

mycophenolate mofetil oral suspension reconstituted 200 mg/ml 237

mycophenolate mofetil oral tablet 500 mg 237

mycophenolate sodium oral tablet delayed release 180 mg, 360 mg 237

N

NATPARA 124

NERLYNX 125

NINLARO 126

nitisinone 127

NOXAFIL ORAL SUSPENSION 147

NUBEQA 128

NUCALA 129

NUEDEXTA 130

NUPLAZID ORAL CAPSULE 74, 75

NUPLAZID ORAL TABLET 10 MG 74, 75

NUTRILIPID INTRAVENOUS EMULSION 20 % 237

O

octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml 131

ODOMZO 132

OFEV 133

olanzapine 74, 75

OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 71

OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED 71

ondansetron hcl injection solution 4 mg/2ml, 40 mg/20ml 237

ondansetron hcl oral solution 4 mg/5ml 237

ondansetron hcl oral tablet 4 mg, 8 mg 237

ondansetron oral tablet dispersible 4 mg, 8 mg 237

ONUREG 134

OPSUMIT 135

ORFADIN ORAL CAPSULE 20 MG 127

ORFADIN ORAL SUSPENSION 127

ORGOVYX 136

ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG 137

ORKAMBI ORAL TABLET 137

OSPHENA 138

oxandrolone oral 139

P

paliperidone er 74, 75

PANRETIN 140

PANZYGA INTRAVENOUS SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML 237

paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg 237

PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML 141

PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 141

PEMAZYRE 142

penicillamine oral tablet 143

pentamidine isethionate inhalation solution reconstituted 300 mg 237

perphenazine oral 74, 75

PIQRAY (200 MG DAILY DOSE) 144

PIQRAY (250 MG DAILY DOSE) 144

PIQRAY (300 MG DAILY DOSE) 144

pirfenidone oral tablet 267 mg, 801 mg 145

PLASMA-LYTE 148 INTRAVENOUS SOLUTION 237

PLASMA-LYTE A INTRAVENOUS SOLUTION 237

PLENAMINE INTRAVENOUS SOLUTION 15 % 237

POMALYST 146

posaconazole 147

prednisolone oral solution 15 mg/5ml 237

prednisolone sodium phosphate oral solution 10 mg/5ml, 20 mg/5ml, 25 mg/5ml, 6.7 (5 base) mg/5ml 237

prednisolone sodium phosphate oral tablet dispersible 10 mg, 15 mg, 30 mg 237

PREDNISONE INTENSOL ORAL CONCENTRATE 5 MG/ML 237

prednisone oral solution 5 mg/5ml 237

prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg 237

prehevbrio intramuscular suspension 10 mcg/ml 237

PREMASOL INTRAVENOUS SOLUTION 10 % 237

PREVYMIS ORAL 148

PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML 237

PROGRAF ORAL PACKET 0.2 MG, 1 MG 237

PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 8

PROMACTA 149

PROSOL INTRAVENOUS SOLUTION 20 % 237

PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML 237

Q

QINLOCK 150

quetiapine fumarate er 74, 75

quetiapine fumarate oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg 74, 75

quinine sulfate oral 151

R

RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED 237

RAVICTI 152

RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 10 MCG/ML (1ML SYRINGE), 40 MCG/ML, 5 MCG/0.5ML, 5 MCG/0.5ML (PREFILLED SYRINGE) 237

REGRANEX 153

REPATHA 154

REPATHA PUSHTRONEX SYSTEM 154

REPATHA SURECLICK 154

RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML 54

RETEVMO 155

REVLIMID ORAL CAPSULE 2.5 MG, 20 MG 156

REXULTI 74, 75

REZUROCK 157

riluzole 158

RINVOQ 159

risperidone 74, 75

ROZLYTREK 160

RUBRACA 161

RYDAPT 162

S

SANDIMMUNE ORAL SOLUTION 100 MG/ML 237

sapropterin dihydrochloride oral packet 163

sapropterin dihydrochloride oral tablet 163

SCEMBLIX 164

SECUADO 74, 75

SIGNIFOR 165

sildenafil citrate oral tablet 20 mg 166

sirolimus oral solution 1 mg/ml 237

sirolimus oral tablet 0.5 mg, 1 mg, 2 mg 237

SIRTURO 167

SKYRIZI (150 MG DOSE) 168

SKYRIZI PEN 168

SKYRIZI SUBCUTANEOUS 168

sofosbuvir-velpatasvir 73

SOLTAMOX 169

SOMAVERT 170

sorafenib tosylate 171

SPRYCEL 172

STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML 173

STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 173

STIVARGA 174

sunitinib malate 175

SUNOSI 176

SYMDEKO 177

SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 178

SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 178

SYNAREL 179

SYNRIBO 180

T

TABRECTA 181

tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg 237

TAFINLAR 182

TAGRISSO 183

TAKHZYRO 184

TALZENNA 185

TASIGNA 186

TAVNEOS 187

tazarotene external cream 188

TAZORAC EXTERNAL CREAM 0.05 % 188

TAZORAC EXTERNAL GEL 188

TAZVERIK 189

TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML 237

TEGSEDI 190

TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION) 237

TEPMETKO 191

teriparatide (recombinant) 192

testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml) 87

testosterone enanthate intramuscular solution 87

testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%) 198

testosterone transdermal solution 198

tetrabenazine 193

THALOMID 194

thioridazine hcl oral 74, 75

thiothixene oral 74, 75

TIBSOVO 195

TIGLUTIK 158

tobramycin inhalation nebulization solution 300 mg/5ml 237

tolvaptan 196

toremifene citrate 199

TPN ELECTROLYTES INTRAVENOUS CONCENTRATE 237

TRAVASOL INTRAVENOUS SOLUTION 10 % 237

TRELSTAR MIXJECT 200

tretinoin external cream 197

tretinoin external gel 0.01 %, 0.025 % 197

TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG 237

trientine hcl 201

trifluoperazine hcl oral 74, 75

TRIKAFTA 202

TROPHAMINE INTRAVENOUS SOLUTION 10 % 237

TRUSELTIQ (100MG DAILY DOSE) 203

TRUSELTIQ (125MG DAILY DOSE) 203

TRUSELTIQ (50MG DAILY DOSE) 203

TRUSELTIQ (75MG DAILY DOSE) 203

TUKYSA 204

TURALIO 205

TYMLOS 206

U

UBRELVY 207

V

VALCHLOR 208

VEMLIDY 72

VENCLEXTA 209

VENCLEXTA STARTING PACK 209

VERQUVO 210

VERSACLOZ 74, 75

VERZENIO 211

vigabatrin 212

VIGADRONE 212

VIJOICE 213

VITRAKVI 214

VIZIMPRO 215

VONJO 216

voriconazole intravenous 217

voriconazole oral 217

VOSEVI 73

VOTRIENT 218

VRAYLAR 74, 75

W

WELIREG 219

X

XALKORI 220

XATMEP ORAL SOLUTION 2.5 MG/ML 238

XGEVA 221

XOLAIR 222

XOSPATA 223

XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG 224

XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG 224

XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG 224

XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG 224

XPOVIO (60 MG TWICE WEEKLY) 224

XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG 224

XPOVIO (80 MG TWICE WEEKLY) 224

XTANDI 225

XYREM 226

XYWAV 227

Y

YONSA 228

Z

ZARXIO 229

ZEJULA 230

ZELBORAF 231

ZIEXTENZO 232

ziprasidone hcl 74, 75

ziprasidone mesylate 74, 75

ZOLINZA 233

ZYDELIG 234

ZYKADIA ORAL TABLET 235